Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
XLO on Nasdaq
Shares outstanding
73,644,024
Price per share
$0.63
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
39,727,815
Total reported value
$25,433,377
% of total 13F portfolios
0%
Share change
+17,967,980
Value change
+$11,324,174
Number of holders
37
Price from insider filings
$0.63
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GILEAD SCIENCES, INC. 20% 0% $9,581,667 +$2,576,464 14,517,678 +37% GILEAD SCIENCES, INC. 31 Dec 2025
Point72 Asset Management, L.P. 9.9% +39% $6,743,200 +$3,371,600 8,000,000 +100% Point72 Asset Management, L.P. 30 Sep 2025
Bain Capital Life Sciences Fund II, L.P. 8.5% $4,131,430 6,259,742 BCLS II Equity Opportunities, LP 31 Dec 2025
STEMPOINT CAPITAL LP 8.4% +17% $3,979,818 +$1,339,818 6,030,028 +51% StemPoint Capital LP 31 Dec 2025
Coastlands Capital LP 10% $3,742,248 5,346,069 Coastlands Capital LP 04 Dec 2025
Frazier Life Sciences Public Fund, L.P. 6.7% -32% $3,086,472 -$2,286,600 4,676,472 -43% Frazier Life Sciences Public Fund, L.P. 31 Dec 2025
AbbVie Inc. 9% $3,304,348 4,347,826 AbbVie Inc. 11 Feb 2025

As of 31 Dec 2025, 37 institutional investors reported holding 39,727,815 shares of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO). This represents 54% of the company’s total 73,644,024 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) together control 54% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
GILEAD SCIENCES, INC. 12% 9,105,451 0% 0.3% $5,829,310
Bain Capital Life Sciences Investors, LLC 10% 7,372,686 +61% 0.36% $4,719,994
Frazier Life Sciences Management, L.P. 8% 5,915,091 0.1% $3,786,841
Point72 Asset Management, L.P. 5.4% 4,000,000 0% $2,560,800
Sio Capital Management, LLC 2.9% 2,134,537 0.23% $1,366,531
STEMPOINT CAPITAL LP 2.8% 2,030,028 0.22% $1,299,624
Merck & Co., Inc. 2% 1,483,758 0% 0.34% $949,902
VANGUARD GROUP INC 1.7% 1,255,692 0% 0% $803,643
Empery Asset Management, LP 1.6% 1,183,040 0% 0.67% $757,382
Ghisallo Capital Management LLC 1.5% 1,113,222 0.03% $712,685
MORGAN STANLEY 1.1% 839,850 -13% 0% $537,672
AJU IB Investment Co., Ltd. 0.91% 667,742 0% 2.3% $427,488
FMR LLC 0.69% 511,820 0% 0% $327,667
CITADEL ADVISORS LLC 0.59% 436,216 0% $279,265
RENAISSANCE TECHNOLOGIES LLC 0.47% 344,416 +68% 0% $220,495
GEODE CAPITAL MANAGEMENT, LLC 0.45% 328,972 0% 0% $210,630
STATE STREET CORP 0.25% 186,390 +14% 0% $119,327
Velan Capital Investment Management LP 0.23% 170,000 0.06% $108,834
GSA CAPITAL PARTNERS LLP 0.2% 147,966 0.01% $95,000
Stonepine Capital Management, LLC 0.17% 126,270 0.06% $80,838
NORTHERN TRUST CORP 0.09% 66,609 0% 0% $42,643
TWO SIGMA INVESTMENTS, LP 0.08% 62,032 -29% 0% $39,713
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.08% 56,081 0% 0% $35,903
JANE STREET GROUP, LLC 0.06% 42,080 0% $26,940
HRT FINANCIAL LP 0.04% 31,886 +29% 0% $20,000

Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 39,727,815 $25,433,377 +$11,324,174 $0.64 37
2025 Q3 22,051,916 $18,613,906 -$1,227,318 $0.84 36
2025 Q2 23,795,263 $16,179,092 +$854,217 $0.68 35
2025 Q1 22,528,206 $16,318,555 -$3,181,066 $0.72 35
2024 Q4 25,814,355 $24,660,128 -$144,644 $0.96 34
2024 Q3 15,911,945 $12,534,583 +$1,128,156 $0.79 32
2024 Q2 14,508,823 $13,746,216 +$1,785,264 $0.95 31
2024 Q1 12,460,895 $13,460,257 -$2,676,053 $1.08 30
2023 Q4 16,426,281 $9,034,716 -$1,543,598 $0.55 33
2023 Q3 15,860,160 $33,465,952 -$314,935 $2.11 30
2023 Q2 16,002,286 $41,925,598 -$192,245 $2.62 32
2023 Q1 16,072,057 $50,979,505 +$461,644 $3.17 32
2022 Q4 15,926,513 $42,841,966 -$709,927 $2.69 28
2022 Q3 16,606,568 $48,328,000 -$3,750,524 $2.91 28
2022 Q2 17,880,380 $52,211,910 -$3,647,986 $2.92 29
2022 Q1 18,775,939 $132,746,000 -$2,569,332 $7.07 41
2021 Q4 18,324,586 $269,421,063 +$225,248,000 $16.00 41